Wedbush Maintains Neutral on Fate Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has maintained a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and lowered the price target from $6 to $3.
November 09, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wedbush has maintained a Neutral rating on Fate Therapeutics and lowered the price target from $6 to $3.
The lowering of the price target by Wedbush from $6 to $3 indicates a negative outlook for the stock. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100